Pathological Conditions

Pathological Conditions and Hyperbaric Oxygen

There are pathological conditions that resist conventional therapeutic approaches not because they are incurable, but because conventional medicine has not yet found an effective way to address the deeper pathophysiological mechanisms that drive them.

Conditions such as Crohn’s disease, fibromyalgia, and chronic fatigue develop against a biological background characterized by chronic inflammation, oxidative stress, mitochondrial dysfunction, and, in many cases, inadequate tissue oxygenation.

Hyperbaric oxygen chamber therapy is incorporated into this field as a biologically targeted adjunctive intervention that acts on these common mechanisms: it improves cellular oxygenation, reduces systemic inflammation, enhances mitochondrial function, and reduces oxidative stress.

It does not treat the disease as an entity but improves the biological conditions under which the body is called upon to address it, while also enhancing the effectiveness of the primary treatment.

Key Characteristics of Pathological Conditions

The common principle of action of hyperbaric oxygen across all pathological conditions in this category is addressing the biological imbalance that characterizes each condition.

For Crohn’s disease, this means improving the oxygenation of inflamed mucosa and suppressing inflammatory cytokines. For chronic fatigue, it means restoring mitochondrial energy production. For fibromyalgia, it means improving muscle oxygenation and addressing neuroinflammation. For inflammatory syndromes, it means systemic anti-inflammatory activity through biological rather than pharmacological mechanisms.

The absence of significant side effects and the non-invasive nature of the treatment make it particularly suitable for patients who are already subject to a substantial medication burden or who are seeking alternative supportive options as part of their treatment.

Scientific Evidence

The scientific evidence for the use of hyperbaric oxygen in pathological conditions is at different stages of maturity depending on the condition. For Crohn’s disease, there are clinical studies with encouraging results, particularly in refractory or inflammatory flares.

For fibromyalgia and chronic fatigue, the data are emerging but promising, with growing research interest. In all cases, the treatment is applied in an adjunctive role and under the supervision of the treating physician or specialist.

The common scientific basis is the documented ability of hyperbaric oxygen to reduce systemic inflammatory markers (CRP, IL-6, TNF-α), improve mitochondrial function, and enhance antioxidant mechanisms—factors that are pathophysiologically involved in all of these conditions.